Fosun Pharma unit gets green light for vaccine trial

Shanghai Fosun Pharmaceutical Group announced that its holding subsidiary, Fosun Anterkin (Chengdu) Biopharmaceutical, has been granted approval from the National Medical Products Administration to conduct clinical trials for its 24-valent pneumococcal polysaccharide conjugate vaccine. The Phase I clinical trial will be conducted in mainland China, excluding Hong Kong, Macau, and Taiwan, pending fulfillment of the necessary conditions. This vaccine is independently developed by Fosun and aims to prevent invasive diseases caused by 24 serotypes of Streptococcus pneumoniae. As of January 2025, Fosun has invested approximately RMB 0.44 billion in the research and development of this vaccine. Currently, no 24-valent pneumococcal polysaccharide conjugate vaccine has been approved for marketing globally. Fosun Pharma cautions that clinical trials involve risks and the vaccine is subject to further regulatory approvals before commercialization.